Author:
Komsta Łukasz,Wicha-Komsta Katarzyna
Abstract
Many forms of drugs are designed to undergo dissolution upon oral administration. The kinetics and efficiency of this process are critical parameters to be controlled. The methods of its evaluation are described in official guidelines issued by the Food and Drug Administration (FDA), European Medicines Agency (EMA) and World Health Organization (WHO). Many approaches of comparison have been proposed, because these guidelines are not limited to a particular mathematical method. This review summarizes the current state of this topic, covering both model-dependent and model-independent methods, as well as multivariate ideas. The references have been chosen to be the most important papers in the field, so that they can be treated by the reader as the best possible recommendations for further reading.
Publisher
Centre for Evaluation in Education and Science (CEON/CEES)
Reference46 articles.
1. Davit BM, Kanfer I, Tsang YC, Cardot J-M. BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements. AAPS J. 2016;18:612-618;
2. Amidon KS, Langguth P, Lennernäs H, Yu L, Amidon GL. Bioequivalence of oral products and the biopharmaceutics classification system: science, regulation, and public policy. Clin Pharmacol Ther. 2011;90(3):467-70;
3. Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413-20;
4. Shah VP, Amidon GL. G.L. Amidon, H. Lennernas, V.P. Shah, and J.R. Crison. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability, Pharm Res 12, 413-420, 1995--backstory of BCS. AAPS J. 2014;16(5):894-8;
5. Chen ML, Amidon GL, Benet LZ, Lennernas H, Yu LX. The BCS, BDDCS, and regulatory guidances. Pharm Res. 2011;28(7):1774-8;